Working… Menu

Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01063270
Recruitment Status : Unknown
Verified March 2013 by Iltefat Hamzavi, Henry Ford Health System.
Recruitment status was:  Active, not recruiting
First Posted : February 5, 2010
Last Update Posted : March 29, 2013
Information provided by (Responsible Party):
Iltefat Hamzavi, Henry Ford Health System

Brief Summary:
The purpose of this research study is to further evaluate the efficacy of two treatment regimens for the treatment of hidradenitis suppurativa. This is a randomized controlled study. Patients will be randomly assigned to an arm of the study.

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa Drug: Clindamycin & Rifampin Procedure: Clindamycin + Rifampin along with NdYag Laser treatment Not Applicable

Detailed Description:
Histological studies suggest that HS is a disease of the follicles with apocrine involvement as a secondary event. The investigators have identified in a previous study that the Nd Yag laser is highly effective for decreasing the inflammation, pain, suppuration and frequency of recurrence of HS. Oral antibiotic therapy with Clindamycin and Rifampin has also been reported in previous studies to be a highly effective treatment regimen for HS and is commonly used by physicians in medical management of HS. The investigators would like to compare the efficacy of NdYag laser treatment combined with antibiotics versus treatment with antibiotics alone. The goal is to evaluate the success of these two treatment regimens on existent HS lesions as well as prevention of recurrence. There will be approximately 18 people in this research study at Henry Ford Health System (HFHS).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Control Trial Comparing Efficacy of Antibiotic Therapy Alone Versus Antibiotic Therapy in Conjunction With Quadruple Pulse Therapy Using NdYag Laser in Treatment of Hidradenitis Suppurativa
Study Start Date : February 2010
Actual Primary Completion Date : July 2011
Estimated Study Completion Date : December 2013

Arm Intervention/treatment
Active Comparator: Antibiotics Drug: Clindamycin & Rifampin
Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks

Active Comparator: Antibiotics and Laser treatment Procedure: Clindamycin + Rifampin along with NdYag Laser treatment
Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.

Primary Outcome Measures :
  1. Number and severity of lesions [ Time Frame: 5 total clinic visits over 6 month period ]

Secondary Outcome Measures :
  1. Change in quality of life during treatment [ Time Frame: 5 total clinic visits over 6 month period ]
  2. Recurrence of disease [ Time Frame: 5 total clinic visits over 6 month period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be at least 16 years old and weigh a minimum of 80lbs. Weight requirement is for the purpose of maintaining safe clindamycin and rifampin dosing regimens.
  2. Be otherwise healthy
  3. Have a diagnosis of HS
  4. Patients must have Hurley stage II HS, with one or more widely separated recurrent abscesses, with tract and scarring. Involvement should be bilateral and symmetric on axillae, inguinal regions or inframammary regions
  5. Agree to abide by the Investigator's guidelines regarding photosensitizing drugs
  6. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
  7. Agree to follow and undergo all study-related procedures

Exclusion Criteria:

  1. Patients with HS Hurley stage I and III will be excluded from participation in the study
  2. Patients who are currently pregnant will not be able to take part in the study due to the unknown effects of antibiotics
  3. Concomitant use of systemic or topical treatments for HS not involved in current study. Patients must discontinue all forms of oral therapy as systemic and topical antibiotics and retinoids for 2 weeks prior to the start of any treatment
  4. Exacerbation of the patient's original condition expressed clinically by a shift from Hurley Stage II to Stage III
  5. Patient is unable to take antibiotic therapy
  6. Any reason the investigator feels the patient should not participate in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01063270

Layout table for location information
United States, Michigan
Henry Ford Hospital Department of Dermatology. 3031 West Grand Blvd, Suite 800
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Henry Ford Health System
Layout table for investigator information
Principal Investigator: Iltefat Hamzavi, M.D. Henry Ford Health System
Layout table for additonal information
Responsible Party: Iltefat Hamzavi, Dermatologist, Henry Ford Health System Identifier: NCT01063270    
Other Study ID Numbers: IRB5974
First Posted: February 5, 2010    Key Record Dates
Last Update Posted: March 29, 2013
Last Verified: March 2013
Keywords provided by Iltefat Hamzavi, Henry Ford Health System:
Hidradenitis Suppurativa
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Bacterial Infections and Mycoses
Skin Diseases, Infectious
Clindamycin palmitate
Clindamycin phosphate
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Leprostatic Agents
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP3A Inducers
Protein Synthesis Inhibitors